Abiomed Stock Forecast, Price & News

Abiomed (NASDAQ:ABMD) Frequently Asked Questions

Is Abiomed a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Abiomed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View analyst ratings for Abiomed or view top-rated stocks.

How has Abiomed's stock been impacted by Coronavirus (COVID-19)?

Abiomed's stock was trading at $151.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABMD stock has increased by 115.7% and is now trading at $325.98.
View which stocks have been most impacted by COVID-19.

Are investors shorting Abiomed?

Abiomed saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 997,800 shares, an increase of 22.0% from the October 31st total of 817,700 shares. Based on an average daily volume of 205,300 shares, the short-interest ratio is presently 4.9 days. Approximately 2.2% of the company's stock are short sold.
View Abiomed's Short Interest.

When is Abiomed's next earnings date?

Abiomed is scheduled to release its next quarterly earnings announcement on Thursday, January 27th 2022.
View our earnings forecast for Abiomed.

How were Abiomed's earnings last quarter?

Abiomed, Inc. (NASDAQ:ABMD) announced its quarterly earnings results on Wednesday, October, 27th. The medical equipment provider reported $1.03 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.98 by $0.05. The medical equipment provider had revenue of $248.10 million for the quarter, compared to analyst estimates of $248.06 million. Abiomed had a trailing twelve-month return on equity of 15.80% and a net margin of 15.32%. The business's quarterly revenue was up 18.3% compared to the same quarter last year. During the same period last year, the business posted $1.01 EPS.
View Abiomed's earnings history.

What guidance has Abiomed issued on next quarter's earnings?

Abiomed issued an update on its FY 2022 earnings guidance on Thursday, November, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.01 billion-$1.03 billion, compared to the consensus revenue estimate of $1.04 billion.

What price target have analysts set for ABMD?

4 brokers have issued 12 month price objectives for Abiomed's stock. Their forecasts range from $245.00 to $425.00. On average, they anticipate Abiomed's stock price to reach $363.75 in the next twelve months. This suggests a possible upside of 11.6% from the stock's current price.
View analysts' price targets for Abiomed or view top-rated stocks among Wall Street analysts.

Who are Abiomed's key executives?

Abiomed's management team includes the following people:

• Michael R. Minogue, Chairman, President & Chief Executive Officer (LinkedIn Profile)
• David M. Weber, Chief Operating Officer & Senior Vice President
• Todd A. Trapp, Chief Financial Officer & Vice President
• Thorsten Sieß, Chief Technology Officer & Vice President
• Charles A. Simonton, Chief Medical Officer

What is Michael R. Minogue's approval rating as Abiomed's CEO?

96 employees have rated Abiomed CEO Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among Abiomed's employees.

Who are some of Abiomed's key competitors?

Some companies that are related to Abiomed include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), DexCom (DXCM), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Masimo (MASI).
View all of ABMD's competitors.

What other stocks do shareholders of Abiomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Square (SQ), Netflix (NFLX), Adobe (ADBE) and salesforce.com (CRM).

What is Abiomed's stock symbol?

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Who are Abiomed's major shareholders?

Abiomed's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.46%), Baillie Gifford & Co. (8.23%), Wellington Management Group LLP (4.42%), Primecap Management Co. CA (3.96%), Renaissance Technologies LLC (3.44%) and Alliancebernstein L.P. (2.15%). Company insiders that own Abiomed stock include Andrew J Greenfield, Dorothy E Puhy, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, Michael R Minogue and Paul Thomas.
View institutional ownership trends for Abiomed.

Which institutional investors are selling Abiomed stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Villere ST Denis J & Co. LLC, Credit Suisse AG, Renaissance Technologies LLC, Wellington Management Group LLP, Primecap Management Co. CA, New York State Common Retirement Fund, Invesco Ltd., and SG Americas Securities LLC. Company insiders that have sold Abiomed company stock in the last year include Andrew J Greenfield, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, and Paul Thomas.
View insider buying and selling activity for Abiomed or view top insider-selling stocks.

Which institutional investors are buying Abiomed stock?

ABMD stock was bought by a variety of institutional investors in the last quarter, including Marathon Asset Mgmt Ltd, Alliancebernstein L.P., Ownership Capital B.V., BlackRock Inc., Baillie Gifford & Co., Moors & Cabot Inc., PEAK6 Investments LLC, and Man Group plc.
View insider buying and selling activity for Abiomed or or view top insider-buying stocks.

How do I buy shares of Abiomed?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abiomed's stock price today?

One share of ABMD stock can currently be purchased for approximately $325.98.

How much money does Abiomed make?

Abiomed has a market capitalization of $14.83 billion and generates $847.52 million in revenue each year. The medical equipment provider earns $225.52 million in net income (profit) each year or $3.24 on an earnings per share basis.

How many employees does Abiomed have?

Abiomed employs 1,725 workers across the globe.

Does Abiomed have any subsidiaries?

The following companies are subsidiares of Abiomed: ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, ABIOMED Limited, ABIOMED R&D, ABIOMED SARL, ABIOMED Singapore Pte. Ltd, AIS GmbH Aachen Innovative Solutions, ECP Entwicklungsgesellschaft mbH, and Impella Cardiosystems.

When was Abiomed founded?

Abiomed was founded in 1981.

What is Abiomed's official website?

The official website for Abiomed is www.abiomed.com.

Where are Abiomed's headquarters?

Abiomed is headquartered at 22 CHERRY HILL DR, DANVERS MA, 01923.

How can I contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at (978) 646-1400, via email at [email protected], or via fax at 978-777-8411.